Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial

Nikolaus Becker, Erna Motsch, Anke Trotter, Claus P Heussel, Hendrik Dienemann, Philipp A Schnabel, Hans-Ulrich Kauczor, Sandra González Maldonado, Anthony B Miller, Rudolf Kaaks, Stefan Delorme, Nikolaus Becker, Erna Motsch, Anke Trotter, Claus P Heussel, Hendrik Dienemann, Philipp A Schnabel, Hans-Ulrich Kauczor, Sandra González Maldonado, Anthony B Miller, Rudolf Kaaks, Stefan Delorme

Abstract

In 2011, the U.S. National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention (LUSI) is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing five annual rounds of LDCT screening (screening arm; n = 2,029 participants) with a control arm (n = 2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 (95% CI: 0.46-1.19; p = 0.21) among men and women combined. Modeling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR = 0.31 [95% CI: 0.10-0.96], p = 0.04), but not among men (HR = 0.94 [95% CI: 0.54-1.61], p = 0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor subtypes occurring in men and women.

Keywords: cancer low-dose CT; lung; randomized trial; screening.

© 2019 UICC.

References

    1. Field JK, van Klaveren R, Pedersen JH, et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol 2013;108:280-6.
    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
    1. Field JK. Perspective: the screening imperative. Nature 2014;513:S7.
    1. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330-8.
    1. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9.
    1. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016;193:542-51.
    1. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009;180:445-53.
    1. Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017;72:825-31.
    1. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308-15.
    1. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol 2012;138:1475-86.
    1. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: results of the first 3 years of follow-up after randomization. J Thorac Oncol 2015;10:890-6.
    1. Baldwin DR, Duffy SW, Wald NJ, et al. UK lung screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011;66:308-13.
    1. Field JK, Duffy SW, Baldwin DR, et al. The UKlung cancer screening trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess (Winchester, England) 2016;20:1-146.
    1. Infante M, Sestini S, Galeone C, et al. Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. Eur J Cancer Prev 2017;26:324-9.
    1. International Association for the Study of Lung Cancer. IASLC Issues Statement on Lung Cancer Screening with Low-Dose Computed Tomography, 2018. Available from: .
    1. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007;120:868-74.
    1. Bade M, Bahr V, Brandt U, et al. Effect of smoking cessation counseling within a randomised study on early detection of lung cancer in Germany. J Cancer Res Clin Oncol 2016;142:959-68.
    1. International Agency for Research on Cancer. IARC handbooks of cancer prevention: breast cancer screening, vol. 7. Lyon: IARC Press, 2002.
    1. Pinsky PF, Church TR, Izmirlian G, et al. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119:3976-83.
    1. Heuvelmans MA, Vliegenthart R, Oudkerk M. Contributions of the European trials (European Randomized Screening Group) in computed tomography lung cancer screening. J Thorac Imaging 2015;30:101-7.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner